Publication Topic

Vincent MJ, Fitch S, Bylsma L, Thompson C, Rogers S, Britt J, Wikoff D. 2024. Assessment of associations between inhaled formaldehyde and lymphohematopoietic cancer through the integration of epidemiological and toxicological evidence with biological plausibility. Toxicol Sci 199(2):172–193; open access.

Yoshino T, Hooda N, Younan D, Muro K, Shitara K, Heinemann V,… Suh M, Reichert H, Mezzi K, Fryzek J, et al. 2024. A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. Eur J Cancer 202:113975, doi: 10.1016/j.ejca.2024.113975.

Vincent M, Fitch S, Bylsma L, Thompson C, Rogers S, Britt J, Wikoff D. Integration of toxicological and epidemiological information to evaluate biological plausibility and causality of associations between inhaled formaldehyde (FA) and lymphohematopoietic (LHP) cancers. Abstract 5157, Society of Toxicology Annual Meeting, Salt Lake City, UT, March 2024. 

Thompson CM, Heintz MM, Cullen JM, Haws LC. 2024. Letter to the Editor of Environmental Pollution: In regard to Wan et al. (2024), “GenX caused liver injury and potential hepatocellular carcinoma of mice via drinking water even at environmental concentration.” Environ Pollut, May 20:124171; doi: 10.1016/j.envpol.2024.1241741.

Yoshino T, Hooda N, Younan D, Shitara K, Heinemann V,… Suh M, Reichert H, et al. 2023. 127P A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness. Ann Oncol 34(Suppl 4):S1519 [abstract]; DOI:https://doi.org/10.1016/j.annonc.2023.10.262.

Thompson CM, Kirman C, Harris MA. 2023. Derivation of oral cancer slope factors for hexavalent chromium informed by pharmacokinetic models and in vivo genotoxicity data. Regul Toxicol Pharmacol 145:105521.

Bylsma LC, Pundole X, Ju CH, Hooda N, Movva N, Elkhouly E, Bebb G, Fryzek J, et al. (in press). Systematic literature review of the prevalence and prognostic value of delta-like ligand 3 protein expression in small cell lung cancer. Target Oncol.

Pundole X, Ju C-H, Bylsma LC, Hooda N, Movva N, Elkhouly E, Bebb DG, Fryzek J, et al. 2023. Prevalence of delta-like ligand 3 expression in small cell lung cancer. J Clinical Oncology 41:16_suppl e20618.

Dalvi T, Nørgaard M, Fryzek JP, Movva N, Pedersen L, Hansen HP, et al. 2023. Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark. PLoS ONE 18(4):e0284037; doi: 10.1371/journal.pone.0284037.

Danese MD, Schenfeld J, Shaw J, Gawade P, Balasubramanian A, Kelsh M, et al. 2022. Association between granulocyte colony-stimulating factor (G-CSF) use and myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) among elderly patients with breast, lung, or prostate cancer. Adv Ther 39(6):2778–2795. doi:10.1007/s12325-022-02141-1.